Yahoo Finance

Eli Lilly’s first quarter was a bit better than Wall Street had anticipated, but it wasn’t enough for traders on Thursday morning, and the stock fell as Novo Nordisk ramped up efforts to claw back weight-loss market share. Lilly’s weight-loss drug is the best available, and the company says it now has 53.3% of the U.S. market for incretin analogues, the class of drugs that includes its medicines Zepbound and Mounjaro. Shares have been climbing, and the stock is up 18.9% over the past 12 months while shares of rival Novo are down 46.4% over the same period.